Eli Lilly's Shares Rise 9% on Strong Sales of Mounjaro and Zepbound, and Raised Forecast
Stock Earnings Results
Eli Lilly's shares surged over +9% August 8th after reporting Q2 earnings that far exceeded expectations, driven by strong sales of its diabetes drug Mounjaro and weight loss injection Zepbound.
The company raised its full-year revenue guidance by $3 billion, expecting $45.4 to $46.6 billion in revenue.
Eli Lilly also increased its adjusted earnings forecast to $16.10 to $16.60 per share. The stock is trading at a P/E of 110 in anticipation of massive earnings growth.
Shares of Eli Lilly are up more than 30% this year after jumping almost 60% in 2023 due to the soaring demand for the company’s weight loss and diabetes drugs – and increased investor interest in their potential as treatments for other health conditions.
That popularity comes despite their hefty monthly price tags, inconsistent insurance coverage and intermittent supply shortages.
With a market cap of more than $730 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better trader.